Soluble intercellular adhesion molecule-1 in serum in chronic hepatitis B and C

Horiike, Norio; Onji, Morikazu; Kumamoto, Izumi; Masumoto, T.

doi:10.1007/bf02361243

Cited by 11 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In chronic hepatitis B and C, greater expression of these molecules has been shown on the hepatocytic membrane, which is related to serum alanine aminotransferase levels [5]. Moreover, some studies have shown an increase in circulating levels of ICAM-1 in chronic hepatitis, confirming the relationship with cytolytic parameters and therefore a possible activation of the immune response [10,30,31]. The present study aimed to evaluate the behaviour of serum ICAM-1 concentrations in patients with CH-C and normal aminotransferase compared with patients with CH-C and elevated aminotransferase, and their changes during ·-IFN 2b therapy.…”

Section: Discussionmentioning

confidence: 69%

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Montalto

Giannitrapani²,

Soresi³

et al. 2003

Intervirology

View full text Add to dashboard Cite

Objectives: Intercellular adhesion molecule-1 (ICAM-1) plays a fundamental role during liver inflammation. In fact, weak ICAM-1 expression is physiologically restricted to the endothelium of portal vessels and to sinusoidal lining cells, but it becomes markedly evident on sinusoidal lining cells and at the surface of hepatocytes during inflammatory liver diseases. The aim of this study was to evaluate the behaviour of soluble ICAM-1 (sICAM-1) in chronic hepatitis C (CH-C) patients with persistently normal aminotransferase in comparison with patients with CH-C and elevated aminotransferase, and its changes during α-interferon (IFN) therapy. Immunohistochemical localization of ICAM-1 was also performed on liver tissue specimens of both groups. Methods: Sixty subjects were divided into 3 groups: group A included 19 patients with CH-C and persistently normal aminotransferase; group B included 21 patients with CH-C and persistently elevated aminotransferase levels, and group C included 20 healthy subjects representing the control group. The first two groups were treated with recombinant α-IFN 2b at a dose of 6 MU 3 times a week for 3 months and followed up with 3 MU 3 times a week for another 3 months. Results: Baseline values of serum ICAM-1 in groups A and B were significantly higher than those in group C (p < 0.0001). The median baseline value of sICAM-1 in group A (525.0 ng/ml) was lower than that of group B (561.0 ng/ml), but the difference was not statistically significant. Furthermore, there was a trend toward higher ICAM-1 values as histological severity increased (Mantel-Haenszel χ² 8.8, p < 0.003). Post-treatment sICAM-1 serum values showed a marked decrease in both groups, but only among responder patients, while ICAM-1 levels were unchanged in non-responders. Immunohistochemical localization showed no staining for ICAM-1 in normal liver specimens, while there was a quite similar staining for ICAM-1 in the two groups of patients, consistent with an inflammatory process. Conclusions: This study shows that circulating ICAM-1 levels in most patients with CH-C and persistently normal aminotransferase are higher than those in a control group and the fact that ICAM-1 molecules are also expressed on the hepatocyte membrane suggests that they could play an important role, in association with other molecules, in the intercellular adhesion processes during the induction and maintenance phases of the immune response. In both groups, only patients responding to α-IFN therapy showed a marked decrease in serum ICAM-1 below baseline values.

show abstract

Section: Discussionmentioning

confidence: 69%

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Montalto

Giannitrapani²,

Soresi³

et al. 2003

Intervirology

View full text Add to dashboard Cite

show abstract

“…Regarding the biological significance of these soluble adhesins in chronic viral hepatitis, a positive correlation with the stage of histological activity seems to exist as well as a fall in serum levels after successful treatment with IFN‐α 19 , . 22 –24 …”

Section: Introductionmentioning

confidence: 99%

Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon‐α

Iacono

García‐Monzón

Almasio

et al. 1998

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: In chronic hepatitis C the relation of circulating adhesion molecules to disease features before, during and after therapy has not been completely established. Aim: To analyse the basal levels of circulating adhesins and the changes induced by interferon in these patients. Methods: We studied, using ELISA assays, the serum levels of soluble intercellular adhesion molecule‐1 (sICAM‐1) and vascular cell adhesion molecule‐1 (sVCAM‐1) in 52 patients with chronic hepatitis C on entry, prior to finalizing a 6‐month course of interferon‐α therapy and at the end of the follow‐up. Correlations with clinical, virological and histological features, including inflammation and fibrosis, were calculated by Pearson’s r‐test. Results: Liver necroinflammation was more closely related to sICAM‐1 (r = 0.54, P = 0.0000) than to sVCAM‐1 (r = 0.32, P = 0.02). Fibrosis, both as serum pIIIP and histological scoring, was, however, clearly related to sVCAM‐1 (1071 ± 291 in patients who scored 0–2 vs. 1870 ± 458 in patients who scored 3–4; P = 0.0000). Severe fibrosis was never found below a sVCAM‐1 cut‐off threshold of 1300 ng/mL. Levels of both adhesins did not correlate with viraemia and were comparable among 1b and non‐1b genotypes. Sustained response to interferon was significantly related to low viraemia (P = 0.03), non‐1b type (P = 0.04) and low sICAM‐1 (P = 0.04), but not to sVCAM‐1. On finalizing therapy, patients with normal transaminases had reduced sICAM‐1 (P = 0.0005), but not sVCAM‐1 levels. Conclusions: In chronic hepatitis C, sICAM‐1 was a marker of liver necroinflammation while sVCAM‐1 reflected fibrosis. Both low sVCAM‐1 and pIIIP serum concentrations were strictly linked, suggesting that measuring sVCAM‐1 could give information on the degree of liver fibroplasia.

show abstract

“…Although sICAM-1 is secreted by various cell types, circulating levels have been suggested to parallel the level of liver inflammation (31,(45)(46)(47). For example, circulating levels of sICAM-1 have been reported to increase in patients who are progressing from chronic hepatitis to cirrhosis and HCC and are strongly correlated with indices of hepatic injury, including alanine aminotransferase (48,49).…”

Section: Discussionmentioning

confidence: 99%

“…High concentration of sTNF-R2 has been observed for prolonged periods in the circulation of patients with various inflammatory diseases, including HCV infection, making sTNF-R2 an ideal serum biomarker to characterize the type 1 immune response (27)(28)(29)(30). Activation of the immune response in chronic hepatitis has also been shown by means of using circulating levels of intercellular adhesion molecule (ICAM)-1 (31,32). Soluble ICAM-1 (sICAM-1) is an important adhesion molecule that is thought to be involved in liver inflammation.…”

Section: Introductionmentioning

confidence: 99%

Host Immune Status and Incidence of Hepatocellular Carcinoma among Subjects Infected with Hepatitis C Virus: A Nested Case-Control Study in Japan

Suruki¹,

Müeller²,

Hayashi

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

A nested case-control study was conducted to examine the association between host immune status, as characterized by serum immune marker levels, and the development of hepatocellular carcinoma (HCC) up to 8 years later in persons with chronic hepatitis C virus (HCV) infection. Cases (n = 39) and matched controls (n = 117) were selected from participants of the Town C HCV Study in Japan between 1996 and 2004 and matched on age at first available sample (F1 year), gender, and length of follow-up. Separate analyses were done for each of three serum immune markers: soluble tumor necrosis factor-receptor II (sTNF-R2) and soluble intercellular adhesion molecule-1 (sICAM-1), as indicators of type 1, cell-mediated immune response, and soluble CD30 (sCD30), as an indicator of type 2, humoral immune response. The median concentrations of sTNF-R2, sICAM-1, and sCD30 among controls were 3,170 pg/mL, 305 ng/mL, and 3.0 units/mL, respectively, and were higher among cases (3,870 pg/mL, 372 ng/mL, and 3.3 units/mL, respectively). The risk of developing HCC among subjects with immune marker concentrations above the median levels of the controls was >2-fold greater than among subjects with lower concentrations for all three markers [sTNF-R2: odds ratio (OR), 6.9; 95% confidence interval (95% CI), 2.4-20.5; sICAM-1: OR, 2.0; 95% CI, 0.9-4.1; and sCD30: OR, 2.1; 95% CI, 1.0-4.7]. Simultaneous adjustment for all three markers revealed only sTNF-R2 to be associated with HCC risk (OR, 6.4; 95% CI, 2.0-20.6). Adjustment for alcohol consumption and HCV serotype did not materially alter these associations. Results from this prospective, community-based study suggest that a dysregulation in both type 1 -related and type 2 -related host immunity contributes to the development of HCV-associated HCC. (Cancer Epidemiol Biomarkers Prev 2006;15(12):2521 -5)

show abstract

Soluble intercellular adhesion molecule-1 in serum in chronic hepatitis B and C

Cited by 11 publications

References 17 publications

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon‐α

Host Immune Status and Incidence of Hepatocellular Carcinoma among Subjects Infected with Hepatitis C Virus: A Nested Case-Control Study in Japan

Contact Info

Product

Resources

About